US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.26 against a street estimate of 0.96 — a beat of 31.3%.
Analysts rate Bausch Health Companies Inc a hold (1 buy, 5 hold, 1 sell out of 7) with an average price target of $7.50.
CONFIDENT BHC delivered 13th consecutive quarter of revenue/EBITDA growth; raised FY26 guidance on strong Salix (+21%), international momentum, and Solta integration success. 2026 tracking significantly ahead of plan. Q2 2026 EMEA sustained organic growth streak. LATAM expansion driven by cardiometabolic franchise. APAC/China integration delivering significant synergies. Canada pressured by anniversary of one-time pricing benefit. Analysts pressed on business development guardrails (BHC open to U.S. Pharma tuck-ins, no leverage increase), post-generic EBITDA sustainability (unchanged 2027 $2.7B pending litigation), and Solta margin trajectory (operating leverage expected as China field force matures; gross margin stable). Management signaled patience on B+L monetization pending Vision 2027 execution. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| Paulson & Company Inc | 19.59% |
| Goldentree Asset Management LP | 9.27% |
| Royal Bank of Canada | 3.04% |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2.14% |
| Vanguard Capital Management, LLC | 1.98% |
| MFN Partners Management, LP | 1.60% |
| Kohlberg Kravis Roberts & Co LP | 1.40% |
| The Goldman Sachs Group Inc | 1.39% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 BAUSCH HEALTH COMPANIES INC. - Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months ended June 30, 2026): $5,376 million ($5,325 mil | 2026-07-30 |
| Results announced · Q3 2026 BAUSCH HEALTH Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total Consolidated Revenues: $2.85 billion in Q2 2026, up 13% reported / 11% organic vs. Q2 | 2026-07-29 |
| Board / officer change · Q2 2026 BAUSCH HEALTH COMPANIES INC. — FORM 8-K SUMMARY Filing Date: June 26, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Board member resignation: Michael Go | 2026-07-01 |
| Shareholder vote results · Q2 2026 BAUSCH HEALTH COMPANIES INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Shareholder Meeting Date: May 19, 2026 • Company: Bausch Health Companies Inc., | 2026-05-19 |
| Quarterly report · Q1 2026 BAUSCH HEALTH COMPANIES INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Quarterly Revenue: $2,524 million (Q1 2026) vs. $2,259 million (Q1 2025) — in | 2026-04-30 |
| Results announced · Q2 2026 BAUSCH HEALTH Q1 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total Consolidated Revenues: $2.52 billion, up 12% reported basis, up 7% organic basis vs. | 2026-04-29 |
| Proxy statement · Q2 2026 BAUSCH HEALTH COMPANIES INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect ten directors for one-year terms exp | 2026-04-08 |
| Annual report FY2025 BAUSCH HEALTH COMPANIES INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Revenues 2025: $10,266 million (up from $9,625 million in | 2026-02-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Reaffirms full year 2025 guidance at higher end of range Bausch Health Companies announced it will present at the J.P. Morgan Healthcare Conference on January 14, 2026, where management will provide strategic and business updates to investors. Mos | 2026-01-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bausch Health Companies Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.